University endowment-backed Will Ventures aims to unlock sports-related innovation across markets such as fitness, media and gaming.

UC Investments has backed cancer cell therapy developer A2 Biotherapeutics, bringing the company's total funding to $136m.

Oncology therapy developer A2 Biotherapeutics raised $71.5m from investors including Hartford HealthCare Endowment to take its funding to $136m altogether.

McKesson Ventures was among the existing investors that provided $25m through a private placement that supported the deal between Augmedix and Malo Holdings.

Kidney disease-focused drug developer Walden was co-founded by faculty members of Rush University and Harvard University earlier this year.

Baidu-backed surgical telemedicine system developer Avail Medsystems notched up a series B round that hiked its overall funding to $125m.

The Novo-backed CAH therapy developer has set the range for an offering set to net it between $60m and $80m in proceeds.

UCB Pharma co-led a series A round for the kidney disease-focused drug developer through its UCB Ventures vehicle.

Medical transcription technology provider Abridge has emerged from stealth with seed and series A funding.

Blood test provider Lumos Diagnostics secured $17.9m and aims to go public in a 2021 IPO that would provide an exit for series A lead investor Planet Innovation.